149 related articles for article (PubMed ID: 38398129)
1. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status.
Hage AM; Gebert P; Blohmer JU; Hedayati E; Speiser D; Karsten MM
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398129
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
Collins JM; Nordstrom BL; McLaurin KK; Dalvi TB; McCutcheon SC; Bennett JC; Murphy BR; Singhal PK; McCrea C; Shinde R; Briceno JM
Oncol Ther; 2021 Dec; 9(2):575-589. PubMed ID: 34308518
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Frenel JS; Lusque A; Delaloge S; Ferrero JM; Bachelot T; Desmoulins I; Levy C; Eymard JC; Gonçalves A; Patsouris A; Reynier MAM; Thery MJ; Petit T; Cabel L; Uwer L; Debled M; Chevrot M; Mailliez A; Jacot W; de La Motte Rouge T
Br J Cancer; 2023 Jun; 128(11):2072-2080. PubMed ID: 37012318
[TBL] [Abstract][Full Text] [Related]
5. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Mutai R; Kuchuk I; Goldshtein A; Yerushalmi R; Rotem O; Maisel Lotan A; Bdolah-Abram T; Gabizon A; Goldvaser H
Breast Cancer Res Treat; 2024 Jun; 205(2):241-248. PubMed ID: 38345692
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A; D'Hondt V; Lusque A; Caron O; Cabel L; Goncalves A; Debled M; Gladieff L; Ferrero JM; Petit T; Mouret-Reynier MA; Eymard JC; Levy C; Uwer L; Leheurteur M; Desmoulins I; Bachelot T; Frenel JS; de la Motte Rouge T; Simon G; Jacot W; Delaloge S
Int J Cancer; 2023 Mar; 152(5):921-931. PubMed ID: 36161271
[TBL] [Abstract][Full Text] [Related]
7. Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status.
Logue CA; Pugh J; Foden P; Mahmood RD; Morgan RD; Mitchell C; Hasan J; Clamp AR; Jayson GC
Sex Med; 2022 Feb; 10(1):100465. PubMed ID: 34922303
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
9. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
[TBL] [Abstract][Full Text] [Related]
10. [Safety of breast-conserving treatment for triple-negative breast cancer].
Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
[TBL] [Abstract][Full Text] [Related]
11. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
12. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
Pavese F; Capoluongo ED; Muratore M; Minucci A; Santonocito C; Fuso P; Concolino P; Di Stasio E; Carbognin L; Tiberi G; Garganese G; Corrado G; Di Leone A; Generali D; Fragomeni SM; D'Angelo T; Franceschini G; Masetti R; Fabi A; Mulè A; Santoro A; Belli P; Tortora G; Scambia G; Paris I
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230495
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
16. Barriers to g
Foroughi O; Madraswala S; Hayes J; Glover K; Lee L; Chaki M; Redpath S; Yu AW; Chiu D; Amanti KG; Gustavsen G
J Pers Med; 2023 Aug; 13(8):. PubMed ID: 37623478
[TBL] [Abstract][Full Text] [Related]
17. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.
Paiella S; Azzolina D; Gregori D; Malleo G; Golan T; Simeone DM; Davis MB; Vacca PG; Crovetto A; Bassi C; Salvia R; Biankin AV; Casolino R
ESMO Open; 2023 Apr; 8(2):100881. PubMed ID: 36822114
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F; Corona SP; Giudici F; Strina C; Sirico M; Bernocchi O; Milani M; Ziglioli N; Aguggini S; Azzini C; Barbieri G; Cervoni V; Cappelletti MR; Molteni A; Lazzari MC; Ferrero G; Ungari M; Marasco E; Bruson A; Xumerle L; Zago E; Cerra D; Loddo M; Williams GH; Paris I; Scambia G; Generali D
Front Oncol; 2021; 11():686776. PubMed ID: 34262869
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of platinum in advanced triple-negative breast cancer with germline
Wang N; Li K; Huang W; Kong W; Liu X; Shi W; Xie F; Jiang H; Song G; Di L; Wang Q; Yu J; Li H
Chin J Cancer Res; 2020 Apr; 32(2):149-162. PubMed ID: 32410793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]